Psilocybin rebuilt brain connections in rats after repeated head knocks

Rats that took psilocybin after repeated mild blows to the head recovered brain connectivity to levels higher than uninjured control animals, a result that has drawn attention from neuroscientists who see an empty space in head-trauma care. The work is animal research only, and no human trial of psilocybin for head injury has been run.

Three days of impacts and a 3 mg/kg dose

The research was led by Craig Ferris, a psychology professor at Northeastern University in Boston, with collaborators including Argel Aguilar-Valles, a neuroscientist at Carleton University in Ontario. In the design Northeastern describes, the team delivered mild impacts to the heads of awake female rats on three consecutive days, without anesthesia, a design intended to mirror the way people experience repeated mild head injuries.

Each treated rat received a single psilocybin injection of 3 milligrams per kilogram of body weight after each impact, as Northeastern’s account of the first, preprint version of the work describes it. Aguilar-Valles told Live Science that this dose is notably higher than the 1 mg/kg often used elsewhere in animal work. A summary of the peer-reviewed paper, published in Communications Biology in 2026, describes three groups of nine-month-old rats: uninjured controls, injured animals without treatment and injured animals given psilocybin, imaged shortly after injury and again three weeks later.

Connectivity, tau and swelling in the rat brain

On MRI and functional MRI, functional connectivity in the treated rats rose across many regions, among them the thalamus, the hippocampus and the basal ganglia. Aguilar-Valles described the recovery as reaching higher levels than in the control group, with the effect showing up “in a lot of brain regions.” That is the basis for describing the connections as rebuilt: in this model, measured connectivity was restored and then exceeded the uninjured baseline.

Other measures moved too. Phosphorylated tau, a protein associated with Alzheimer’s disease and with repeated head trauma, fell to near control levels in the paper’s description. Markers of brain swelling from fluid leakage, known as vasogenic edema, were reduced. Brain-derived neurotrophic factor, a molecule that supports neuron growth, and its receptor TrkB rose, according to a News-Medical summary of the study.

Ferris called the preprint results striking: “It actually improves these neuroradiological measures associated with head injury,” he said, according to Northeastern, which described the study as the first report of psilocybin treating brain injury.

The sample was small. In the preprint, ScienceAlert reported, the injured groups totalled 16 adult female rats against 8 uninjured comparison animals, and the authors acknowledged the limit. Those group sizes come from the earlier version, and the published paper’s numbers could not be checked for this article. The animals were all female, which limits what can be said about males, and the injury model was repeated and mild rather than severe, so the result speaks to a narrow slice of head trauma.

Caveats the researchers attach to the rat result

The restraint in the researchers’ own language is considerable. The published paper notes that behavioral benefits were limited and that whether the biological changes translate into lasting neurological protection, or into benefits for people, remains unknown. The preprint had reported normal cognitive and motor recovery, so the two versions differ on what the animals could do afterward, and the later, peer-reviewed wording is the more cautious. Higher-than-control connectivity is also not obviously a pure benefit, since it is a measurement of signal coupling and the accounts read do not say that more connectivity equals better function.

Carleton’s release quotes Aguilar-Valles saying that psilocybin is not ready to be considered a treatment for concussion, and warning against self-medicating after a head injury. He described the study as conducted primarily in female rats, with treatment given within 30 minutes of the injury, and listed dose, timing and translation to humans as unknowns, which is the standard set of caveats for any first-generation animal result.

The gap the work targets is real, though. The work resurfaced on October 3, when Live Science published an interview with Aguilar-Valles about it, though the study itself was reported earlier in 2026. Aguilar-Valles told Live Science that there is no drug treatment for head trauma care, which is why a compound that appears to act on inflammation and neural plasticity attracts interest. He also raised open questions: whether the effects last for months after dosing, and what the drug would do in a developing brain.

The evidence still missing is a controlled human trial, and none exists for this use. Ferris has said future experiments will examine treating injuries long after they occur, a delay that would resemble the situation of athletes and veterans more closely than dosing within half an hour of impact, and a harder test of whether the rat result carries any weight for people.

This article was produced with the assistance of AI and reviewed by Morning Overview editors prior to publication.

More from Morning Overview